Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coca-Cola FUZE purchase cleared

This article was originally published in The Tan Sheet

Executive Summary

Coca-Cola confirmed on March 2 FTC has approved its acquisition of FUZE Beverages without requiring any changes to the deal. The firm announced Feb. 1 its plan to purchase the FUZE Beverage line including lines Vitalize, Slenderize, Refresh and Tea (1"The Tan Sheet," Feb. 26, 2007, In Brief)...

You may also be interested in...



Food claim warning letter

Labeling for several FUZE Healthy Infuzions beverages stating vitamin B3 is "known to ... reduce cholesterol levels in blood" and polyphenols are "associated with reduced risk of developing cardiovascular disease and certain cancers" violates the Food, Drug & Cosmetic Act, FDA says in a recent 1warning letter to FUZE Beverages. These claims "promote [the] products for use as drugs." Additionally, the products "are labeled with a dietary supplement disclaimer statement," the agency adds. "Because these products are conventional foods, not dietary supplements, their labels should not include this disclaimer." The dietary supplement industry voiced its concerns to FDA at a recent meeting and asked that dietary supplements and functional foods be given a level "regulatory playing field" (2"The Tan Sheet" Dec. 11, 2006, p. 3). Coca-Cola announced Feb. 1 it intends to purchase FUZE to expand its beverage portfolio...

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel